Oral mucositis is a painful inflammatory condition affecting the mucosal lining of the mouth, most frequently arising as a direct consequence of cytotoxic chemotherapy or head-and-neck radiation therapy. Severity ranges from mild redness and tenderness to extensive ulceration that impairs a patient’s ability to eat, swallow, and maintain adequate oral hygiene.
Clinical Significance
Oral mucositis affects up to 40% of patients receiving standard chemotherapy regimens and nearly all patients undergoing high-dose conditioning before hematopoietic stem cell transplantation. Beyond acute pain, severe mucositis can lead to systemic infection, unplanned treatment interruptions, prolonged hospitalization, and significant nutritional compromise. Early identification and supportive care are critical to preserving both quality of life and treatment continuity.
Common Causes and Risk Factors
- Chemotherapy agents, particularly methotrexate, 5-fluorouracil, and melphalan
- Radiation therapy directed at the head, neck, or oropharynx
- mTOR inhibitors and certain immunotherapies
- Pre-existing periodontal disease, which increases the mucosal bacterial burden
- Xerostomia (dry mouth), which reduces saliva’s natural buffering and protective capacity
How It Develops
Mucositis typically appears within 5–10 days of initiating treatment. The oral epithelium breaks down in progressive stages, advancing from erythema to pseudomembranous ulceration. Lesions preferentially affect non-keratinized surfaces — the buccal mucosa, lateral tongue, soft palate, and floor of the mouth — rather than the more resilient, keratinized gingival tissue and hard palate.
Grading and Management
Severity is graded on the WHO or NCI-CTCAE scale from Grade 1 (mild soreness, erythema) to Grade 4 (life-threatening ulceration requiring nutritional support). Management approaches include low-level laser therapy to promote mucosal healing, palifermin (keratinocyte growth factor) for high-risk transplant patients, topical analgesics, and rigorous basic oral care protocols such as gentle toothbrushing and saline rinses. Because disrupted mucosa creates a direct portal for fungal and bacterial pathogens, infection surveillance — including monitoring for Candida overgrowth — is integral to care.
Pre-treatment dental assessment to resolve active caries and periodontal disease measurably reduces mucositis severity, making dental clearance before cancer therapy an important preventive step for any at-risk patient.